Welcome to Alpha-GalCer.net where you will find the most comprehensive information about Alpha-GalCer and 7DW8-5 glycolipids, research papers, protocols, symposiums, clinical updates and more.  Alpha-GalCer is a fascinating compound and has potential for wide clinical applications and detrimental scientific community continues investigating Alpha-GalCer potentials.  This potent glycolipid has demonstrated significant activities such as anti-tumor, anti-viral and enhanced immune regulation.   The objective of this website is to create awareness from this important compound, bring together Alpha-GalCer researchers, educate and broaden the scientific knowledge of Alpha-GalCer research with the ultimate goal of improving human quality of lives.

You will find within this website an introduction of Alpha-GalCer (KRN7000), mechanism, lists of clinical applications being investigated, anti-tumor activities by tumor type, immunotherapy, general protocols, patent information, scientific meetings, clinical updates and where to obtain KRN7000.  All of this information can be accessed from the navigation menu on the left side of this website.

Note: Alpha-GalCer (KRN7000) is for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of Kyowa Hakko Kirin Company. Kyowa Hakko Kirin Company has issued a worldwide license for KRN7000 research to Funakoshi Company.


Click green circles below for your application of interest:

Overview graphic of Alpha-Galcer (KRN7000) Adjuvant research using KRN7000 Microbiology research with KRN7000 Introduction to Alpha-Galcer (KRN7000)




New 7DW8-5 glycolipid


Now available 7DW8-5 glycolipid derivative of Alpha-GalCer for human and mice iNKT immunoresearch

Meet Funakoshi Company
at the following meetings:

Due to Covid-19. there are no scheduled conferences for 2021 at this time.